Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantourage Group SEFRA:HIGH 20 EV-to-EBIT is 1,344.24 as of Aug. 09, 2026. GuruFocus rates FRA:HIGH with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 686 Drug Manufacturers companies, Cantourage Group SE ranks worse than 99.85% on this metric.
Cantourage Group SE (FRA:HIGH) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cantourage Group SE's Enterprise Value for the quarter that ended in Jun. 2025 was €64.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cantourage Group SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE EV-to-EBIT Related Terms
Cantourage Group SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HIGH vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's EV-to-EBIT falls into.
Cantourage Group SE's current Enterprise Value is €60.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cantourage Group SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE (FRA:HIGH) has a EV-to-EBIT of 1,344.24 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cantourage Group SE and its competitors. According to the industry distribution chart, Cantourage Group SE ranks #685 out of 686 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Cantourage Group SE's EV-to-EBIT too high?
Cantourage Group SE's current EV-to-EBIT is 1,344.24. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Cantourage Group SE's value of 1,344.24 is 8448.4% above this industry median. Based on the distribution chart, Cantourage Group SE ranks #685 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cantourage Group SE has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #685 out of 686 companies for EV-to-EBIT. This places Cantourage Group SE in the lower half of its industry. The industry median EV-to-EBIT is 15.73. Cantourage Group SE's value of 1,344.24 is 8448.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current EV-to-EBIT of 1,344.24 is 8448.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current EV-to-EBIT is 1,344.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (FRA:HIGH) has a current EV-to-EBIT of 1,344.24. The current EV-to-EBIT is 1,344.24 and 8448.4% above the Drug Manufacturers industry median of 15.73. Cantourage Group SE's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cantourage Group SE (FRA:HIGH), the current EV-to-EBIT is 1,344.24 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
20GF Score
Get the complete analysis for FRA:HIGH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HIGH has been successfully added to your 
